Eli lilly’s AI CRM bet fuels veeva’s soaring profits

The gist

Eli Lilly’s global rollout of Veeva’s AI-native Vault CRM is supercharging pharma engagement—and fueling Veeva’s record profits—even as execution risks loom.

What to know

AI Transforms Pharma Engagement

Eli Lilly’s adoption of Veeva Vault CRM marks a leap in AI-driven commercial operations, automating field interactions and accelerating medicine delivery through agentic call reporting.

Eli Lilly's global expansion of Veeva Vault CRM marks a strategic leap in leveraging AI-driven commercial platforms to modernize pharmaceutical engagement and accelerate medicine delivery. By adopting Vault CRM as the core infrastructure for Veeva’s 'agentic commercial' framework, Lilly is enhancing operational efficiency and streamlining healthcare provider interactions through AI-powered features like Agentic Call Reports, which automate call note synthesis and reduce administrative burdens. Giuseppe Firenze, Senior VP of Commercial Operations at Lilly, emphasized that Vault CRM will help bring breakthrough medicines to more patients, underscoring the platform’s pivotal role in Lilly’s broader AI-driven transformation across commercial, clinical, and manufacturing domains.

The deepening partnership between Eli Lilly and Veeva exemplifies the convergence of enterprise software innovation with biopharmaceutical operations, reflecting a maturation of agentic AI from experimental technology to an industry-standard commercial tool. Veeva CEO Peter Gassner highlighted that with over 180 customers live on Vault CRM across 100+ countries, the platform’s industry-specific AI capabilities are delivering tangible customer success, signaling robust market validation for Veeva’s next-generation AI-native CRM system built on Salesforce infrastructure. This collaboration not only enhances Lilly’s field engagement but also illustrates the growing integration of AI to optimize pharmaceutical commercial workflows globally.

Sources

Veeva’s AI Ambitions and Risks

Veeva’s aggressive AI-enabled expansion, fueled by acquisitions and new agentic platforms, is reshaping pharma workflows but exposes the company to scaling challenges and customer concentration risks.

Eli Lilly's global adoption of Veeva Vault CRM exemplifies Veeva's strategic pivot towards AI-enabled commercial platforms, positioning the company as a critical technology backbone for AI-driven life sciences commercial models. This deployment, anchored by recent AI innovations like Vault AI and the Falcon agentic labor platform, highlights Veeva's commitment to embedding autonomous AI agents into workflows to enhance operational efficiency and drive adoption. However, this ambitious expansion also underscores execution risks, particularly regarding customer concentration and the challenge of scaling AI capabilities across large pharmaceutical enterprises.

Veeva's financial trajectory supports its AI-driven transformation, with Q1 fiscal 2027 revenues reaching $883 million and a robust 45% EBIT margin, providing a strong foundation to fund its compute-intensive digital labor model. CEO Peter Gassner’s introduction of the FIAP architecture—integrating models, agents, and applications—signals a clear vision to replace specific human tasks with autonomous AI agents, as evidenced by the launch of Veeva Falcon targeting clinical trial documentation and safety case automation. Despite the complexity and cost of this shift, Veeva's profitability and raised R&D guidance reflect investor confidence in its AI CRM growth ambitions.

Strategic acquisitions like Ostro have materially enhanced Veeva’s commercial platform by expanding brand engagement capabilities and enabling real-time, legally compliant responses to healthcare professionals and patients. The integration of Ostro with Veeva’s Open Evidence product creates a powerful commercial evidence platform that aggregates unfiltered medical queries, offering pharma companies actionable insights to swiftly address messaging barriers and improve medicine access. This acquisition-driven growth contributed approximately $10 million to commercial subscription revenue guidance, illustrating a blend of organic and inorganic growth fueling Veeva’s evolving product mix.

While Veeva's traditional CRM business currently accounts for about 20% of total revenue, it is projected to decline to roughly 10% by 2030 as newer AI-driven products accelerate growth, reflecting a successful diversification strategy that aims to transform Veeva into the comprehensive operating system for life sciences. The company’s fiscal 2027 guidance anticipates 13% growth in both total revenue and subscriptions, supported by strong recent financials including $3.195 billion in full-year revenue and $1.434 billion in non-GAAP operating income. This shift towards long-term annual guidance over quarterly billings signals management’s confidence in sustained AI CRM expansion despite modest EBIT margin compression from increased services investments.

Sources

Investor Debate: Veeva’s AI Future

Veeva’s AI-powered CRM dominance faces scrutiny as investors weigh execution risks, margin pressures, and the critical need to win over pharma’s largest holdouts for sustained growth.

Veeva Systems is widely recognized as a dominant $3 billion force in life sciences software, successfully driving industry-wide adoption of its Vault platform while integrating AI to automate routine tasks, which fuels bullish investor sentiment about its AI CRM growth potential. However, market views remain cautious due to the unpredictable timing and impact of AI-driven advancements, with both bullish and bearish cases hinging on how effectively Veeva can execute and scale AI adoption across pharma customers.

Bearish perspectives highlight significant execution risks for Veeva, including a slowdown in clinical data growth and declining relevance of its core CRM as growth rates mature to the low teens. The company’s future upside heavily depends on securing the remaining five of the top 20 pharmaceutical companies yet to commit to Vault CRM, a critical factor determining whether Veeva can cement its monopoly or face competition from custom Salesforce builds.

Investors express concern about the margin implications of Veeva’s AI initiatives, given the company’s historically robust 45% operating margins. While management acknowledges that AI revenue will not materially impact FY27 financials, uncertainty remains whether the token-based AI pricing model will enhance profitability or if heavy AI development and compute costs will pressure margins, making the financial payoff of AI investments a key watchpoint.

Within the broader pharmaceutical industry context, AI is seen as an enabling technology that improves operational efficiency—such as speeding patient recruitment and automating regulatory documentation—but it cannot accelerate the fundamental biological timelines of drug development. This tempered view, echoed by CEO Peter Gassner, underscores that while AI-driven platforms like Veeva Vault CRM are strategically important, their transformative impact has natural limits tied to the realities of clinical trial durations.

Sources
VC10X with Prashant ChoubeyThe Earnings Debate

Lilly’s Financial Firepower

Eli Lilly’s surging revenue and record cash flow are powering bold investments in AI partnerships like Veeva, while rewarding shareholders and reinforcing its leadership in pharmaceutical innovation.

Eli Lilly's robust financial performance, highlighted by a 56% revenue surge in Q1 2026 compared to the previous year and a strong gross margin of 82.6%, is largely fueled by the successful launch of its GLP-1 therapies. This financial strength underpins the company’s strategic capital allocation, enabling it to confidently expand investments in innovative partnerships like the AI-driven Veeva Vault CRM platform. Reflecting this confidence, management raised its 2026 revenue guidance by $2 billion to a range of $82 billion to $85 billion, alongside an increase in non-GAAP earnings per share expectations to between $35.50 and $37, signaling sustained growth and operational efficiency that support such technology collaborations.

Beyond top-line growth, Eli Lilly’s robust cash flow generation empowers a balanced capital strategy that simultaneously rewards shareholders and fuels innovation. In Q1 2026 alone, the company returned $1.5 billion in dividends and repurchased $2.4 billion in shares, demonstrating strong shareholder commitment. This financial flexibility also facilitates strategic investments in growth avenues, including technology partnerships like the one with Veeva, positioning Lilly to leverage AI-driven commercial platforms to enhance pharmaceutical engagement and operational efficiency.

Sources
The Earnings Debate

Get the stories behind the trends

Deep-dive reporting and the weekly brief, in your inbox.